NDA 218475 · Baxter Hlthcare Corp
Epinephrine Bitartrate In 0.9% Sodium Chloride
Epinephrine Bitartrate · Intravenous
Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 28, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
933
108 Phase 3, 77 recruiting
FAERS reports
42,335
26,333 serious, 3,545 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 19, 2026.
Epinephrine in 0.9% Sodium Chloride Injection is a non-selective alpha- and beta-adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine in 0.9% Sodium Chloride Injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
Mechanism: Epinephrine acts on both alpha (α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Epinephrine Bitartrate" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological OutcomePivotal-lookingNot yet recruiting
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT07442071 · 4,336 participants (planned) · Start Jun 2026 · Primary completion Jul 2030
Drug: Epinephrine 0.5 mg intravenous bolus; Epinephrine 1 mg intravenous bolus · For: Out-of-hospital Cardiac Arrest (OHCA)
Sites: Annecy, France; Bayonne, France; Besançon, France · 26 sites in all
- Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal IndomethacinPivotal-lookingTerminated
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT03057769 · 3,300 participants · Start Feb 1, 2017 · Primary completion Oct 26, 2017
Drug: Papillary epinephrine spraying; Papillary saline spraying and 1 more · For: Pancreatitis; Endoscopic Retrograde Cholangiopancreatography
Sites: Xiamen, China; Lanzhou, China; Ankang, China · 10 sites in all
- Diagnosis of PheochromocytomaRecruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004847 · 3,000 participants (planned) · Start Mar 22, 2000 · Primary completion Nov 30, 2048
Drug: ([18F]-DOPA); ([18F]-6F-DA) · For: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Sites: Bethesda, Maryland
- Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac ArrestPivotal-lookingCompleted
Hospices Civils de LyonAcademic, hospital or other
NCT00127907 · 2,416 participants · Start May 2, 2004 · Primary completion Oct 1, 2007
Drug: epinephrine (1 mg/1 mL); arginine-vasopressin (40 UI/2 mL) · For: Cardiac Arrest
Sites: Pierre-Bénite, France
- Sodium Bicarbonate in Cardiopulmonary ResuscitationPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01377337 · 2,130 participants (planned) · Start Dec 2011 · Primary completion Dec 2013
Drug: sodium bicarbonate · For: Sudden Cardiac Arrest
Sites: Haifa, Israel; Tel Aviv, Israel
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT01700192 · 1,482 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: MK-8237 tablets; Placebo tablets and 4 more · For: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,536
- headache3,074
- sinusitis2,919
- fatigue2,801
- product dose omission issue2,780
- pain2,488
- covid-192,424
- dyspnoea2,269
- nausea2,230
- pneumonia2,076
- off label use2,065
- inappropriate schedule of product administration1,785
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 133 |
| 2005 | 118 |
| 2006 | 136 |
| 2007 | 166 |
| 2008 | 194 |
| 2009 | 269 |
| 2010 | 261 |
| 2011 | 702 |
| 2012 | 425 |
| 2013 | 301 |
| 2014 | 411 |
| 2015 | 635 |
| 2016 | 1,057 |
| 2017 | 1,572 |
| 2018 | 2,477 |
| 2019 | 3,337 |
| 2020 | 6,460 |
| 2021 | 3,909 |
| 2022 | 3,582 |
| 2023 | 3,781 |
| 2024 | 4,431 |
| 2025 | 4,735 |
| 2026 | 3,240 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single buccal infiltrations for maxillary first molars in patients with irreversible pulpitis: a randomized controlled clinical trial.
Atasoy Ulusoy Ö, Alaçam T · Int Endod J 2014 · Randomized Controlled Trial
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.